Synergistic effects of trastuzumab and 9-cis-RA on HER2/neu positive breast cancer cells implanted to nude mice

郎海滨; 糜漫天; 朱俊东

您当前的位置：

首页 >

文章列表页 >

Synergistic effects of trastuzumab and 9-cis-RA on HER2/neu positive breast cancer cells implanted to nude mice

更新时间：2026-01-09

- Synergistic effects of trastuzumab and 9-cis-RA on HER2/neu positive breast cancer cells implanted to nude mice
- Journal of Army Medical University Vol. 30, Issue 17, Pages: 1601-1603(2008)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：
  CLC： R737.9;R977.21;R979.19
- Published：2008
- 稿件说明：
移动端阅览
郎海滨,糜漫天,朱俊东.赫赛汀和9-顺式视黄酸联合用药对HER2阳性荷瘤鼠乳腺癌细胞的抑制效应[J].陆军军医大学学报(原第三军医大学学报),2008,30(17):1601-1603.

　LANG Hai-bin,MI Man-tian,ZHU Jun-dong.Synergistic effects of trastuzumab and 9-cis-RA on HER2/neu positive breast cancer cells implanted to nude mice[J].J Amry Med Univ (J Third Mil Med Univ),2008,30(17):1601-1603.
郎海滨,糜漫天,朱俊东.赫赛汀和9-顺式视黄酸联合用药对HER2阳性荷瘤鼠乳腺癌细胞的抑制效应[J].陆军军医大学学报(原第三军医大学学报),2008,30(17):1601-1603. DOI：

　LANG Hai-bin,MI Man-tian,ZHU Jun-dong.Synergistic effects of trastuzumab and 9-cis-RA on HER2/neu positive breast cancer cells implanted to nude mice[J].J Amry Med Univ (J Third Mil Med Univ),2008,30(17):1601-1603. DOI：

摘要

目的探讨赫赛汀和9-顺式视黄酸单独和联合用药对HER2阳性乳腺癌细胞周期进程的体内协同抑制效应及其分子机制。方法将处于对数生长期的MCF-7

HER2

细胞皮下注射到BALB/c裸鼠体内，用赫赛汀和9-顺式视黄酸分别单独和联合处理裸鼠移植瘤模型20d，测量各组裸鼠移植瘤的体积大小。利用免疫印记法检测移植瘤细胞HER2、P27、Cyclin E和CDK2蛋白的表达变化。结果赫赛汀和9-顺式视黄酸联合作用组较对照和单独作用组能显著减小HER2阳性乳腺癌细胞裸鼠移植瘤的体积，二者联合运用还能在体内显著改变荷瘤鼠癌细胞HER2、P27、Cyclin E和CDK2的表达。结论联合应用赫赛汀和9-顺式视黄酸可在体内通过对细胞周期相关蛋白的表达进行调控从而达到协同抑制HER2阳性乳腺癌细胞的作用。

Abstract

Objective To observe the synergistic effects of trastuzumab and 9-cis-RA on HER2/neu positive breast cancer cells in vivo. Methods MCF-7 breast cancer cells transfected with exogenous HER2 gene were inoculated into nude mice. Four weeks later

the mice bearing a tumor of approximately 200 mm

in volume were selected to be treated with trastuzumab and/or 9-cis-RA (SC) for 20 d. Then the tumor volume was precisely measured

simultaneously the protein expressions of Cyclin E

CDK2 as well as P27 in the tumor tissues were detected by Western blot assay. Results The combination of trastuzumab and 9-cis-RA synergistically decreased the tumor v

olume

compared with control group and single medication group. Western blot results showed that the Cyclin E and CDK2 expressions were significantly inhibited

while P27 protein expressions were remarkably up-regulated by the co-treatment. Conclusion Trastuzumab and 9-cis-RA could synergistically inhibit the proliferation of HER2 positive breast cancer cells in vivo by influencing the protein expressions of G

phase-related molecules.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

A novel estrogen receptor expression stratification (low/moderate/high) based on Chinese population provides more accurate prognosis prediction for HR⁺/HER2^- early breast cancer patients

Sulfasalazine antagonizes boosted metastasis of breast cancer induced by ionizing radiation

Effect of transmembrane protein 196 on migration and invasion of breast cancer

Effect of circular RNA hsa_circ_0000231 interacting with HnRNPK on proliferation, migration, and apoptosis in breast cancer

Circular RNA circACTN4 promotes proliferation, invasion and metastasis of breast cancer cells

Related Author

WANG Chengfang

ZHOU Yuqin

ZHANG Yanling

QI Xiaowei

ZHANG Yi

Ge HE

Guojian WANG

Na ZHAO

Related Institution

Department of Breast and Thyroid Surgery， First Affiliated Hospital， Army Medical University （Third Military Medical University）

State Key Laboratory of Trauma, Burns and Combined Injury, Department of Anti-Radiation Medicine, Chongqing Engineering Research Center for Nanomedicine, Institute of Combined Injury, Faculty of Military Preventive Medicine, Army Medical University (Third Military Medical University)

Department of Breast and Thyroid Surgery, the Second Affiliated Hospital of Chongqing Medical University

Department of Environmental Health, College of Military Preventive Medicine, Army Medical University (Third Military Medical University)

Institute of Toxicology, College of Military Preventive Medicine, Army Medical University (Third Military Medical University)

⁰